See more : Aro Granite Industries Limited (AROGRANITE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Roche Holding AG (RHHBY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Roche Holding AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- CyberTAN Technology, Inc. (3062.TW) Income Statement Analysis – Financial Results
- Valneva SE (VLA.PA) Income Statement Analysis – Financial Results
- Hypebeast Limited (HYPPF) Income Statement Analysis – Financial Results
- Nanjing Baose Co., Ltd. (300402.SZ) Income Statement Analysis – Financial Results
- Laboro.AI Inc. (5586.T) Income Statement Analysis – Financial Results
Roche Holding AG (RHHBY)
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 60.44B | 63.28B | 62.80B | 58.32B | 61.47B | 56.85B | 53.30B | 50.58B | 48.15B | 47.46B | 46.78B | 45.50B | 42.53B | 47.47B | 49.05B | 45.62B | 46.13B | 42.04B | 35.51B | 31.27B | 31.22B | 29.73B | 29.16B | 28.67B | 27.57B | 24.66B |
Cost of Revenue | 16.36B | 20.40B | 19.65B | 16.18B | 18.35B | 17.27B | 18.18B | 16.18B | 15.46B | 13.38B | 11.95B | 12.18B | 11.94B | 13.29B | 14.62B | 13.66B | 13.74B | 10.62B | 9.30B | 7.18B | 8.32B | 8.43B | 8.34B | 9.16B | 8.87B | 7.90B |
Gross Profit | 44.08B | 42.88B | 43.15B | 42.15B | 43.12B | 39.58B | 35.12B | 34.40B | 32.69B | 34.08B | 34.83B | 33.32B | 30.59B | 34.18B | 34.44B | 31.96B | 32.39B | 31.43B | 26.21B | 24.09B | 22.91B | 21.29B | 20.82B | 19.51B | 18.69B | 16.76B |
Gross Profit Ratio | 72.94% | 67.77% | 68.72% | 72.26% | 70.14% | 69.62% | 65.89% | 68.01% | 67.89% | 71.81% | 74.46% | 73.24% | 71.92% | 72.00% | 70.20% | 70.05% | 70.21% | 74.75% | 73.80% | 77.03% | 73.37% | 71.63% | 71.41% | 68.04% | 67.81% | 67.96% |
Research & Development | 14.20B | 16.02B | 14.80B | 13.01B | 12.77B | 12.09B | 11.29B | 11.53B | 9.58B | 9.90B | 9.27B | 9.55B | 8.33B | 10.03B | 9.87B | 8.85B | 8.39B | 6.59B | 5.71B | 5.09B | 4.77B | 4.26B | 3.89B | 3.95B | 3.78B | 3.41B |
General & Administrative | 14.88B | 2.89B | 3.33B | 3.04B | 4.12B | 5.26B | 3.43B | 1.72B | 2.73B | 3.84B | 2.65B | 3.05B | 2.34B | 2.87B | 2.18B | 2.33B | 2.45B | 2.54B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
Selling & Marketing | 0.00 | 9.64B | 9.92B | 9.57B | 10.96B | 10.11B | 9.85B | 9.14B | 8.81B | 8.66B | 8.37B | 8.54B | 8.05B | 9.49B | 9.48B | 9.17B | 9.33B | 10.86B | 9.51B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 14.88B | 12.53B | 13.25B | 12.61B | 15.08B | 15.37B | 13.27B | 10.86B | 11.54B | 12.50B | 11.02B | 11.59B | 10.39B | 12.36B | 11.65B | 11.50B | 11.78B | 13.40B | 11.91B | 10.41B | 10.30B | 9.83B | 9.67B | 9.99B | 8.99B | 7.83B |
Other Expenses | -392.00M | -192.00M | -238.00M | -265.00M | -227.00M | -197.00M | -311.00M | -316.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 28.69B | 25.41B | 25.00B | 23.60B | 25.57B | 24.83B | 22.12B | 20.33B | 18.86B | 19.99B | 18.46B | 19.21B | 17.15B | 20.71B | 19.45B | 18.06B | 17.92B | 19.71B | 17.54B | 15.11B | 17.31B | 19.96B | 17.58B | 12.38B | 12.27B | 12.39B |
Cost & Expenses | 45.05B | 45.81B | 44.65B | 39.78B | 43.92B | 42.10B | 40.30B | 36.51B | 34.32B | 33.37B | 30.40B | 31.39B | 29.09B | 34.01B | 34.06B | 31.72B | 31.67B | 30.33B | 26.84B | 22.29B | 25.63B | 28.39B | 25.92B | 21.54B | 21.15B | 20.29B |
Interest Income | 183.00M | 67.00M | 342.00M | 16.00M | 99.00M | 30.00M | 30.00M | 22.00M | 24.00M | 34.00M | 27.00M | 32.00M | 73.00M | 51.00M | 179.00M | 698.00M | 1.07B | 788.00M | 423.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 997.00M | 690.00M | 419.00M | 553.00M | 791.00M | 744.00M | 765.00M | 958.00M | 1.11B | 1.18B | 1.33B | 2.00B | 2.01B | 2.55B | 2.44B | 214.00M | 281.00M | 315.00M | 264.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 3.46B | 3.82B | 4.45B | 4.57B | 4.31B | 3.60B | 3.89B | 3.95B | 3.64B | 2.62B | 2.38B | 2.42B | 2.37B | 2.55B | 2.69B | 2.65B | 2.54B | 2.44B | 1.01B | 1.61B | 1.51B | 1.52B | 1.55B | 2.85B | 2.45B | 2.07B |
EBITDA | 18.54B | 20.86B | 22.86B | 23.08B | 21.70B | 22.51B | 21.19B | 17.91B | 16.74B | 19.13B | 18.99B | 16.24B | 16.29B | 16.27B | 15.50B | 16.48B | 18.12B | 15.34B | 9.68B | 10.58B | 7.10B | 2.86B | 4.80B | 27.57B | 8.87B | 6.44B |
EBITDA Ratio | 30.67% | 34.02% | 36.40% | 38.58% | 35.37% | 31.95% | 31.52% | 35.38% | 35.44% | 35.03% | 39.76% | 37.30% | 38.48% | 34.69% | 37.52% | 36.12% | 37.31% | 33.97% | 27.26% | 33.84% | 22.75% | 9.60% | 16.46% | 34.80% | 32.19% | 26.13% |
Operating Income | 15.40B | 17.48B | 18.16B | 18.54B | 17.55B | 14.77B | 13.00B | 14.07B | 13.82B | 14.09B | 16.38B | 14.13B | 13.45B | 13.49B | 12.28B | 13.92B | 14.47B | 11.73B | 8.67B | 8.98B | 5.59B | 1.34B | 3.25B | 7.13B | 6.42B | 4.37B |
Operating Income Ratio | 25.47% | 27.62% | 28.91% | 31.79% | 28.55% | 25.98% | 24.40% | 27.82% | 28.71% | 29.69% | 35.01% | 31.04% | 31.63% | 28.41% | 25.03% | 30.52% | 31.36% | 27.90% | 24.41% | 28.71% | 17.91% | 4.49% | 11.13% | 24.87% | 23.29% | 17.72% |
Total Other Income/Expenses | -1.32B | -1.15B | -757.00M | -578.00M | -934.00M | -621.00M | -755.00M | -1.06B | -1.83B | -1.58B | -1.70B | -1.97B | -1.57B | -2.28B | -2.05B | 237.00M | 836.00M | 857.00M | 133.00M | 506.00M | -711.00M | -4.53B | 1.52B | 2.34B | 1.13B | 1.08B |
Income Before Tax | 14.08B | 16.33B | 17.40B | 17.97B | 16.61B | 14.15B | 12.25B | 13.01B | 11.99B | 12.52B | 14.68B | 12.32B | 11.89B | 11.21B | 10.23B | 14.16B | 15.30B | 12.59B | 8.97B | 9.49B | 4.88B | -3.19B | 4.76B | 9.47B | 7.56B | 5.45B |
Income Before Tax Ratio | 23.29% | 25.80% | 27.70% | 30.80% | 27.03% | 24.89% | 22.98% | 25.72% | 24.90% | 26.37% | 31.37% | 27.08% | 27.94% | 23.62% | 20.86% | 31.04% | 33.17% | 29.94% | 25.25% | 30.33% | 15.63% | -10.75% | 16.33% | 33.02% | 27.41% | 22.11% |
Income Tax Expense | 1.72B | 2.80B | 2.46B | 2.90B | 2.51B | 3.28B | 3.42B | 3.27B | 2.93B | 2.98B | 3.30B | 2.55B | 2.34B | 2.32B | 1.72B | 3.32B | 3.87B | 3.44B | 2.22B | 2.35B | 1.45B | 839.00M | 1.04B | 2.27B | 1.90B | 965.00M |
Net Income | 11.50B | 12.42B | 13.93B | 14.30B | 13.50B | 10.50B | 8.63B | 9.58B | 8.86B | 9.33B | 11.16B | 9.43B | 9.34B | 8.67B | 7.78B | 8.97B | 9.76B | 7.88B | 5.92B | 6.61B | 3.07B | -4.03B | 3.70B | 8.65B | 5.76B | 4.39B |
Net Income Ratio | 19.02% | 19.63% | 22.18% | 24.51% | 21.96% | 18.47% | 16.20% | 18.93% | 18.41% | 19.66% | 23.86% | 20.72% | 21.97% | 18.25% | 15.87% | 19.66% | 21.16% | 18.74% | 16.68% | 21.12% | 9.83% | -13.54% | 12.68% | 30.16% | 20.91% | 17.81% |
EPS | 14.31 | 1.94 | 2.05 | 2.09 | 1.97 | 1.54 | 1.26 | 1.41 | 1.30 | 1.37 | 1.65 | 1.39 | 1.38 | 1.27 | 1.13 | 1.30 | 1.42 | 1.16 | 0.88 | 0.98 | 0.46 | -0.60 | 0.55 | 1.29 | 0.84 | 0.64 |
EPS Diluted | 14.30 | 1.94 | 2.03 | 2.07 | 1.95 | 1.53 | 1.25 | 1.39 | 1.29 | 1.35 | 1.62 | 1.38 | 1.37 | 1.26 | 1.13 | 1.28 | 1.40 | 1.13 | 0.86 | 0.97 | 0.45 | -0.60 | 0.55 | 1.28 | 0.84 | 0.64 |
Weighted Avg Shares Out | 803.49M | 6.40B | 6.80B | 6.84B | 6.85B | 6.83B | 6.82B | 6.82B | 6.81B | 6.79B | 6.78B | 6.78B | 6.79B | 6.84B | 6.86B | 6.88B | 6.87B | 6.82B | 6.76B | 6.72B | 6.71B | 6.71B | 6.72B | 6.72B | 6.90B | 6.90B |
Weighted Avg Shares Out (Dil) | 804.00M | 6.40B | 6.88B | 6.92B | 6.91B | 6.88B | 6.88B | 6.88B | 6.90B | 6.90B | 6.90B | 6.84B | 6.81B | 6.86B | 6.87B | 6.89B | 6.90B | 6.90B | 6.88B | 6.80B | 6.80B | 6.71B | 6.90B | 6.76B | 6.90B | 6.90B |
Roche: The Devil Is In The Details - Obesity Data Presentation Disappoints
Roche launches the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche's role in pioneering cervical cancer solutions
TG Therapeutics: A Look At New Briumvi Data And Ocrevus Zunovo Approval
Roche Antiviral Drug Reduces Transmission in Late-stage Study
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
"Everyone Should Applaud" Powell for 50bps: Cullen Roche
Healthy Returns: How competitive can Roche be in the weight loss drug market?
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
Source: https://incomestatements.info
Category: Stock Reports